Vera Therapeutics Analyst Ratings
Vera Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Wedbush Raises Vera Therapeutics' Price Target to $34 From $21 After Model Update, Maintains Neutral Rating
Analysts Conflicted on These Healthcare Names: Inspire Medical Systems (INSP), ACELYRIN, INC. (SLRN) and Vera Therapeutics (VERA)
Buy Rating Affirmed on Vera Therapeutics Ahead of Key Atacicept Clinical Milestones
Wedbush Reaffirms Their Hold Rating on Vera Therapeutics (VERA)
Vera Therapeutics Analyst Ratings
Buy Rating Affirmed for Vera Therapeutics on Promising IgAN Drug Trial Results
Vera Therapeutics' Atacicept Shows Potential in IgAN Treatment: A Buy Rating With a $25 Price Target
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Ocular Therapeutix (OCUL)
Vera Therapeutics Analyst Ratings
Vera Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Vera Therapeutics, Maintains $25 Price Target
Vera Therapeutics Analyst Ratings
Vera Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $22
Vera Therapeutics Analyst Ratings
Hold Rating on Vera Therapeutics Amid Uncertainties and Upcoming Data Release: A Financial Analysis
Jefferies Upgrades Vera Therapeutics to Buy, Raises Price Target to $26
No Data